In a post-pandemic world, we need to explore a broader view of our new reality. This article shares some of the concepts currently playing out in biopharmaceutical outsourcing that will impact your CDMO selection strategy. Additional discussion touches on how new outsourcing players will fit in and the path forward.
Changes in raw materials are inevitable over a drug's lifespan, but even small modifications can throw your drug out of compliance. Learn how to safeguard drug integrity when raw materials change.
Three studies cover a product that aims to address unmet needs around the development of subcutaneous drug therapies for chronic disease treatment, including methods for sterilization and a human factors evaluation.
An ongoing strategic growth plan is expanding our manufacturing capacity and services across geographies so that we are able to better meet increased demand and have improved lead times for key products.
